KRAS and lung carcinoma: In contrast, regarding KRAS oncogene, although the KRAS-MAPK pathway is downstream of EGFR signaling, KRAS-mutation driven lung cancers, which are mainly adenocarcinomas, do not respond to EGFR tyrosine kinase inhibitors (TKIs) [12].